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ABSTRACT:
Many bladder cancers progress to invasion with poor prognosis; new therapeutic 
methods are needed. We developed a cytotoxic LH-RH analog, AN-152 (AEZS-108) 
containing doxorubicin (DOX), for targeted therapy of cancers expressing LHRH 
receptors. We investigated the expression of LH-RH receptors in clinical bladder 
cancers and in HT-1376, J82, RT-4 and HT-1197 human bladder cancer lines. The effect 
of analog, AN-152, on growth of these tumor lines xenografted into nude mice was 
analyzed. Using molecular and functional assays, we also evaluated the differences 
between the effects of AN-152, and DOX alone. We demonstrated the expression of 
LH-RH receptors on 18 clinical bladder cancers by immunohistochemistry and on four 
human urinary bladder cancer lines HT-1376, J82, RT-4 and HT-1197 by Western 
blotting and binding assays. AN-152 powerfully inhibited growth of these bladder 
cancers in nude mice. AN-152 exerted greater effects than DOX and was less toxic. 
DOX activated strong multidrug resistance mechanisms in RT-4 and HT-1197 cancers, 
while AN-152 had no or less such effect. PCR assays and in vitro studies revealed 
differences in the action of AN-152 and DOX on the expression of genes involved in 
apoptosis. These results suggest that targeted cytotoxic LH-RH analog, AN-152 (AEZS-
108), should be examined for treatment of patients with LH-RH receptor positive 
invasive bladder cancers.
INTRODUCTION
Yearly almost 400,000 new cases of urinary bladder 
cancer are diagnosed in the world and more than 150,000 
people die of the disease [1]. In the US, bladder cancer is 
the fifth most frequent malignancy and the most expensive 
tumor to treat [2]. Approximately 75% of bladder cancers 
are diagnosed at an early stage; half of these progress to 
invasive tumor [2].
Chemotherapy for the treatment of metastatic or 
recurrent transitional cell carcinoma of the urinary tract 
began decades ago. Doxorubicin (DOX) and cisplatin 
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as single agents or in various combinations showed 
efficacy in the treatment of advanced bladder cancer and, 
in combinations with  cyclophosphamide, methotrexate, 
vinblastine, reached response rates of 90% [3, 4]. The 
combination of methotrexate, vinblastine, adriamycin 
and cisplatin (M-VAC) increased median survival of 
patients up to 12.5 months [5]. These response rates were 
accompanied by significant systemic toxicity and frequent 
relapse due to resistance to additional therapy [5-7]. 
Combinations of gemcitabine and cisplatin show response 
rates similar to the M-VAC [8] with less severe side effects 
and are considered a standard of care for patients with 
metastatic disease [9]. 
Elucidation of the molecular characteristics of 
urothelial cancers introduced possibilities for targeted 
therapies.  Receptors for growth factors appear to play 
a role in progression of urothelial carcinoma [10]. Thus, 
targeting receptor tyrosine kinases, e.g. EGF, Her-2/neu, 
or manipulation of signal transduction pathways provide 
new therapeutic strategies [11, 12] but require molecular 
analyses to select patients who would benefit [13]. 
The demonstration of receptors for neuropeptide 
hormones on various tumor cells [14-16] led to 
development of cytotoxic peptides and peptide hormones 
linked to radionuclides for tumor diagnosis and therapy 
[17-19]. Radiolabeled analogs of somatostatin, bombesin 
or vasoactive intestinal peptide (VIP) are now increasingly 
used for tumor imaging and therapy [17-19]. Our group 
synthesized analogs of LH-RH, somatostatin, and 
bombesin linked to DOX which selectively target tumors 
expressing the specific receptors while sparing normal 
tissues from toxicity. These analogs inhibit growth of 
various experimental human cancers, and are more 
effective and tolerable than the cytotoxic radical, DOX, 
alone [17-19]. 
Initially, receptors for LH-RH were demonstrated on 
human breast, endometrial, ovarian, and prostatic cancers 
[17-20]. Subsequently expression of these receptors was 
also found on human non-Hodgkin’s lymphomas [21], 
renal cell carcinomas [22] and malignant melanomas [23], 
suggesting the potential of targeted therapy with cytotoxic 
analogs of LH-RH. Cytotoxic LH-RH analog, AN-152 
(AEZS-108), showed promising results in phase II clinical 
trials in women with several gynecological cancers [24, 
25] and is now in phase I/II clinical trials for patients with 
prostate [26] and bladder cancers [19, 27]. In this study we 
investigated the expression of LH-RH receptors in clinical 
human urinary bladder specimens and in four human 
bladder cancer cell lines. We also analyzed the effect of 
cytotoxic LH-RH analog, AN-152 (AEZS-108), on growth 
of human experimental tumors xenografted into nude 
mice. We compared the effect of AN-152 and its cytotoxic 
radical, DOX, by molecular and functional assays. 
RESULTS
LH-RH receptor expression in human bladder 
cancer 
Eighteen human primary urothelial cancer samples 
were evaluated by immunohistochemistry. Positive 
staining for LH-RH receptors was observed in all 
specimens (Fig. 1 a-c). Enhanced staining of the plasma 
membrane as well as cytoplasmic staining were detected 
in malignant cells and the positive control (human anterior 
pituitary) (Fig. 1d). In three samples, high levels of LH-
RH receptor expression with more than 75% positively 
stained malignant cells was found, two samples revealed 
weak expression; 13 samples were intermediate. 
Expression was variable; areas of high, distinct and low 
LH-RH receptor density were sometimes seen within one 
sample. In these cases, the dominating receptor density 
was chosen for final categorization. In surrounding 
non-malignant tissue no or marginal LH-RH receptor 
expression was found (Fig. 1a-c).
Effect of treatments on tumor growth in nude 
mice
In Experiment 1, AN-152 strongly inhibited HT-
1376 cancers. Tumor volume and tumor weights were 
significantly less than control (Fig. 2a) (Table 1). In 
contrast, DOX, Cetrorelix and [D-Trp6]LH-RH had no 
effect on tumor growth. The median growth rate values 
of the tumors treated with AN-152 and DOX differed 
significantly (P=0.018). Body and organ weights were 
Figure 1:Expression of LH-RH receptors in 
human bladder carcinomas. The tissue was stained by 
immunohistochemistry with primary LH-RH receptor antibody. 
A-C: urothelial bladder carcinoma;  D: positive control, anterior 
pituitary. 
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similar in all groups, except for ovarian weights, which 
were lower in the AN-152 group (also in Experiments 3 
and 4) (data not shown).
In Experiment 2 (Fig. 2b), both AN-152 and DOX 
at first powerfully inhibited growth of J82 tumors.  The 
tumors treated with DOX started regrowing at day 80 
while those treated with AN-152 continued inhibition. At 
the end of the experiment, AN-152 produced a significant 
(84%) reduction in volume. The DOX decrease was less 
(76%) and not significantly different from control. Tumor 
weights and body weights were lower than control in both 
treated groups (Table 1). The mice that received DOX 
were emaciated; their mean weight was significantly 
lower than that of controls or animals treated with AN-
152 (Table 1). 
In Experiment 3, AN-152 strongly inhibited 
growth of RT-4; the tumors did not resume growth after 
treatment cessation (Fig. 2c). DOX initially reduced RT-4 
proliferation, the tumors started growing more intensely 
after treatment cessation.  Tumor weights were also lower 
after treatment with AN-152, but not DOX (Table 1). 
DOX again significantly lowered animal body weights 
(Table 1).
In Experiment 4, both AN-152 and DOX produced 
a substantial volume reduction of HT-1197 cancers; the 
effect of AN-152 was significantly greater than that of 
DOX (Fig. 2d). Tumor weights were lower only in the 
group receiving AN-152 (Table 1). DOX significantly 
reduced the weights of mice at day 29, these remained 
significantly lower to the end of the experiment (Table 
1). Thus, Group 2 received another AN-152 injection on 
day 30, but DOX was discontinued because of systemic 
Figure 2:Effect of treatment with cytotoxic LH-RH analog, AN-152 (AEZS-108), and doxorubicin (DOX), on growth of 
human bladder cancers in nude mice. The vertical bars represent SE. Solid arrows show treatments with both cytotoxic compounds, 
dashed arrow shows treatment only with AN-152 (2d).
Oncotarget4www.impactjournals.com/oncotarget
toxicity. 
Receptor assays and Western blots
Radiolabeled [D-Trp6]LH-RH was bound to a single 
class of specific binding sites on all four cancer lines. 
The concentrations of LH-RH receptors and the binding 
affinity varied slightly among the tumor models, as shown 
in supplementary Table S1. LH-RH receptor protein (38 
KD) was detected in all four tumors by Western blotting, 
the levels of receptor protein being not significantly 
different between treated group and control (Fig. 3).
Molecular analysis
Using the Cancer Drug Resistance and Metabolism 
PCR Array, we analyzed the expression of 84 genes that 
may influence response to chemotherapy. The assays 
involve genes related to drug resistance, drug metabolism, 
DNA repair, transcription, and cell cycle regulation, as 
well as those encoding receptors for growth factors and 
hormones. Three bladder cancer lines (J82, RT-4 and 
HT-1197) were investigated and the results are presented 
in Figures 3-4. The degree and pattern of changes in 
gene expression were different in each of the three. J82 
showing the least and HT-1197 the strongest, alterations. 
In J82 tumor, genes related to drug resistance were not 
changed, except ABCC2 (ATP-binding cassette, sub-
family B, member 1), which was reduced by DOX. In 
RT-4 cancers, DOX produced a moderate increase of 5 
and a minor decrease of 4 genes, while AN-152 caused a 
slight decrease in 6. Practically all drug resistance genes 
were overexpressed in HT-1197 tumors treated with either 
agent; the increase was much greater after DOX (Fig. 
4a). Nearly all genes involved in drug metabolism were 
increased by DOX in all tumors, while treatment with 
AN-152 caused only slight amplifications of these genes 
in HT-1197. (Fig. 4b). Genes engaged in DNA repair 
were not affected by either treatment in J82, moderately 
changed in RT-4 and strongly increased in HT-1197 
tumors; DOX therapy induced stronger alterations (Fig. 
4c). Fig. 4d demonstrates that genes encoding cyclines and 
Figure 3:Detection LH-RH receptor protein (38 KD) by 
Western blotting. All four human urinary bladder cancer lines 
grown in nude mice expressed LH-RH receptors.  Representative 
blots of three independent experiments are shown. 
Table 1: Growth characteristics of human urinary bladder cancers in nude mice and 
changes in body weights of the animals after treatment with LH-RH analogs AN-152 or 
DOX 
Groups Tumor volume (mm3) Tumor weights (mg) Body weights (g)
        Experiment 1 HT-1376
1. Control 999 ± 375 900 ± 340 27.3 ± 1.5
2. Cetrorelix 1154 ± 438 623 ± 124 28.6 ± 0.6
3. [D-Trp6]LH-RH 1007 ± 349 648 ± 161 24.6 ± 0.6
4. AN-152 377 ± 240 256 ± 139* 26.2 ± 0.9
5. DOX 858 ± 365 396 ± 96 24.2 ± 0.6*
        Experiment 2 J82
1. Control 1456 ± 493 1256 ± 384 29.2 ± 0.9
2. AN-152 238 ± 111* 360 ± 181 24.3 ± 0.9*
3. DOX 351 ± 131 386 ± 181 21.6 ± 0.6*†
        Experiment 3 RT-4
1. Control 2824 ± 961 1353 ± 532 24.6 ± 0.6
2. AN-152 416 ± 313* 475 ± 339* 24.3 ± 1.1
3. DOX 1613 ± 764 868 ± 673 22.0 ± 1.6*
        Experiment 4 HT-1197
1. Control 563 ± 152 527 ± 173 28.9 ± 1.5
2. AN-152 60 ±20* 54 ± 30* 25.3 ± 0.9
3. DOX 150 ± 38*† 70 ± 23 23.1 ± 1.1*
Values are means  ± SE.       *P<0.05 vs. Control       †P<0.05 vs. AN-152 group
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Figure 4:Human urinary bladder cancers grown in nude mice were analyzed with the Human Cancer Drug Resistance 
& Metabolism RT Profiler PCR Array The vertical bars on the left shows 10-fold change compared to control. *= 
P<0.05 vs. control.
(A)Changes in genes involved in drug resistance. ABCB1: ATP-binding cassette, subfamily B, member 1; ABCC1-6: ATP-binding 
cassette, subfamily C, members 1-6;  ABCG2: ATP-binding cassette, subfamily G, member 2; BAX: BCL2-assiciated X protein; BCL2: 
B-cell CCL/lymphoma 2; BCL2L1: BCL2-like 1; MVP: Major vault protein; RB1: Retinoblastoma 1; TOP1: Topoisomerase (DNA) I; 
TOP2A: Topoisomerase (DNA) II alpha; TOP2B: Topoisomerase (DNA) II beta; TP53: Tumor protein p53.
(B)Changes in genes involved in drug metabolism. ARNT: Aryl hydrocarbon receptor nuclear translocator; BLMH: Bleomycin 
hydrolase; CLPTM1L: Cleft lip and palate transmembrane protein 1-like protein (cisplatin resistance-related protein); CYP1A1, 
CYP1A2, CYP2B6, CYP2C19, CYP2C8, CYP2C9, CYP2D6, CYP2E1, CYP3A4, CYP3A5: Cytochrome P450, family 1-3, subfamily 
A-D, polypeptide 1-19; DHFR: Dihydrofolate reductase; EPHX1: Epoxide hydrolase , microsomal (xenobiotic); GSK3A: Glycogen 
synthase kinase 3 alpha; GSTP1: Glutathione S-transferase pi 1; NAT2: N-acetyltransferase 2; SOD1: Superoxide dismutase 1; SULT1E1: 
Sulfotransferase family 1E, estrogen-preferring, member 1; TPMT: Thiopurine S-methyltrasferase.
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cycline dependent kinases were similarly changed by the 
two compounds, while DOX caused a stronger increase 
in kinase inhibitors. Regarding growth factors and their 
receptor genes, DOX increased EGF receptor (EGFR ), 
ErbB2, ErbB4 (V-erb-b2 erythroblastic leukemia viral 
oncogene homolog 2 and 4), fibroblast growth factor 2 
FGF2 and IGF-1 receptor (IGF-1R) in various tumors, 
while AN-152 therapy resulted in small increases in 
ErbB2, ErbB4 and FGF2 in HT-1197 cancers only (Fig. 
4e). Increased expression in a variety of hormone receptor 
genes was the strongest in HT-1197 tumors, with DOX 
having a much greater  effect than AN-152 (Fig. 4f). 
Genes related to transcription factors were mostly down-
regulated in RT-4 and up-regulated in HT-1197 cancers; 
DOX had a more powerful effect in the latter (Fig. 4g).
We also used the Human Apoptosis PCR Array 
to detect changes in expression of 84 genes involved in 
programmed cell death.  Anti-apoptotic gene expression 
was increased by DOX in all three tumors, affecting a few 
genes only in J82, more in RT-4 and the most in HT-1197. 
AN-152 resulted in a moderate increase in anti-apoptosis 
genes in HT-1197 cancers (Supplementary Fig. S1a). 
Regarding pro-apoptotic genes, DOX produced stronger 
increases than AN-152 in RT-4 tumors (Supplementary 
Fig. S1b). 
Protein analysis by Western blot showed increases 
in anti-apoptotic proteins, Bcl2 and BclX, in all treated 
tumors (results not shown), more in those treated with 
DOX. The differences were statistically not significant. 
Multi-drug resistance and apoptosis assays in 
vitro
The MDR study showed that treatment with either 
cytotoxic compound resulted in a retention of calcein in all 
three tumor cell lines, but the retention was significantly 
higher after treatment with AN-152 than DOX. The 
greatest differences between the effect of AN-152 and 
DOX were in RT-4 and HT-1376 and the least in J82 (Fig. 
5a). Apoptosis assay in vitro revealed that AN-152 had a 
stronger apoptogenic effect than DOX on RT-4 and HT-
1376 tumor cells, while both compounds acted similarly 
on J82 cells (Fig. 5b). 
DISCUSSION
Siegel et al [28] estimate that 73,510 new cases 
of urinary bladder cancer will be diagnosed in the US 
in 2012 with 14,880 estimated deaths. The numbers of 
newly diagnosed cases and deaths are high and require 
improvement [28]. The estimated 5-year cost of care to 
Medicare is approximately one billion dollars [29]. 
Platinum based regimens are currently the standard 
of therapy but metastatic urothelial cancer remains a 
deadly and costly disease [5, 29, 30]. More research with 
novel, targeted agents is needed to improve outcomes [29]. 
Targeted therapies are being widely investigated 
and increasingly used for treatment of various tumors. 
Targeting produces an improvement in tumor effect and 
diminishes systemic toxicity [17-19, 27]. Peptide hormone 
receptors present on various cancer cells, can function as 
targets for specific compounds composed of cytotoxic 
agents conjugated to peptide analogs. The peptide 
hormone serves as a carrier molecule for homing the 
cytotoxic agent to target cells containing specific receptors. 
Thus, we have developed cytotoxic compounds containing 
DOX conjugated to an LH-RH agonist, tested them on a 
variety of experimental tumor models, and showed that 
they are more effective and less toxic than unconjugated 
DOX [17-19, 25, 27]. Besides the pituitary, receptors for 
LH-RH have been detected in various human cancer cell 
Figure 4:Human urinary bladder cancers grown in nude mice were analyzed with the Human Cancer Drug Resistance 
& Metabolism RT Profiler PCR Array The vertical bars on the left shows 10-fold change compared to control. *= 
P<0.05 vs. control.
(C)Changes in genes involved in DNA repair. 1: APC: Adenomatous polyposis coli; ATM: Ataxia teleangiectasia mutated; BRCA1, 
BRCA2: Breast cancer 1, 2; ERCC3: Excision repair cross-complementing rodent repair deficiency, complementation group 3 (xeroderma 
pigmentosum group B complementing); MSH2:MutS homolog 2, colon cancer, nonpopyposis type 1; XPA, XPC: Xeroderma pigmentosum, 
complementation group A, C.
(D)Genes involved in cell cycle. CCND1, CCNE1: Cyclin D1, E1; CDK2, CDK4: Cyclin dependent kinase 2, 4; CDKN1A, CDKN1B, 
CDKN2A: CDKN2D: Cyclin-dependent kinase inhibitor 1A, 1B, 2A, 2D.
(E)Changes in growth factor genes. EGFR: Epidermal growth factor receptor; ERBB2, ERBB3, ERBB4: V-erb-b2 erythroblastic 
leukemia viral oncogene homolog 2, 3, 4:FGF2: Fibroblast growth factor 2; IGF1R, IGF2R: Insulin-like growth factor 1, 2 receptor; MET: 
Met proto-oncogene (hepatocyte growth factor receptor).
(F)Hormone receptor genes. AR: Androgen receptor;ESR1, ESR2: Estrogen receptor 1, 2; PPARA, PPARD, PPARG: Peroxisome 
proliferator-activated receptor alpha, beta, gamma; RARA, RARB, RARG: Retioic acid receptor alpha, beta, gamma; RXRA, RXRB: 
Retinoid X receptor alpha, beta.
(G)Genes related to transcription factors. AHR: Aryl hydrocarbon receptor; AP1S1: Adaptor-related protein complex1, sigma 
1 subunit; ELK1: ELK1, member of ETS oncogene family; FOS: FBJ murine osteosarcoma viral oncogene homolog; HIF1A: Hypoxia 
inducible factor 1, alpha subunit;  MYC: V-myc myelocytomatosis viral oncogene homolog; NFKB1, NFKB2, NFKBIB, NFKBIE: Nuclear 
factor of kappa light polypeptide gene enhancer in B cells1, 2, inhibitor beta, epsilon; RELB: V-rel reticuloendotheliosis viral oncogene 
homolog B; TNFRSF11A: Tumor necrosis factor receptor superfamily, member 11a.
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lines and human cancer specimens. These include prostate, 
breast, ovarian and endometrial cancers and other cancers, 
which are outside of the reproductive system, such as 
renal cell carcinoma, melanoma, Hodgkin’s lymphoma 
and colorectal cancers [18, 19]. The expression of peptide 
hormone receptors on bladder cancers has been minimally 
investigated. Only one group verified the expression of 
LH-RH receptors in human bladder epithelium , bladder 
cancers and bladder cancer cell lines, but did not detect 
any effect of LH-RH on bladder cancer cells in vitro [31]. 
This study reveals the presence of LH-RH receptors 
(LH-RH R) in all 18 specimens of bladder cancer patients. 
We also demonstrated LH-RH R expression by molecular 
methods and binding assays of LH-RH receptors in all 
four human bladder cancer lines investigated. The four cell 
lines used are transitional cell carcinomas originating from 
bladder, but with various degrees of differentiation and 
differing in characteristics and behavior. Thus, HT-1376 
originated from a grade 3 carcinoma with a functional 
loss mutation in p53; RT-4 is a transitional cell papilloma 
with wild-type p53. Clinical relevance of various tumor 
cell lines is linked to the clinical tumor behavior [32]. 
RT-4 cancer is associated with long survival, low grade, 
and low invasiveness. In contrast, J82 corresponds to high 
grade and invasion; HT-1376 has the shortest survival. 
The diversity of the four tumor lines investigated makes 
the study more clinically relevant. These cell lines also 
have varying sensitivity to DOX, as treatment with 
DOX inhibited growth of J82 and HT-1197 tumors, but 
not HT-1376 and RT-4 cancers. The four tumors showed 
consistent inhibition in response to AN-152, which had a 
stronger effect and was less toxic than DOX. 
To damage tumor cells, anti-cancer drugs must 
enter the cell through the cell membrane, and remain 
for the time necessary for their action, avoiding several 
defensive mechanisms. Resistance affects many unrelated 
drugs and is therefore called multidrug resistance [33-
35]. Some cancers are intrinsically resistant to specific 
drugs, others initially respond, but develop resistance 
during treatment. Drug resistant cells may overgrow 
during therapy and secondary genetic changes induced 
by a drug can lead to increased therapeutic resistance 
Figure 5:Effects of AN-152, and DOX on HT-1376, J82 and RT-4 human urinary bladder cancer cells in vitro. 5a: 
calcein retention in the cells analyzed with MDR Assay Kit and 5b: apoptosis investigated with the Multi-Parameter Apoptosis Assay. 
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[34]. One mechanism in tumor cells is the drug-efflux 
system that consists of various molecules belonging to 
the ABC transporter family, and which can eject drugs 
such as DOX from the cells. ABC transporters include 
P-glycoproteins, (MDR1, multi drug resistance protein 
1; ABCB1, ATP-binding cassette sub-family B, member 
1), MRP1 (multi-drug resistance associated protein 1) 
and other related compounds [33, 35]. Gene expression 
analysis can elucidate specific resistance pathways [36]; 
identifying differences to drugs such as DOX, cisplatinum, 
or paclitaxel [37]. 
Most bladder carcinomas are initially sensitive to 
chemotherapy, but the majority develop resistance [38]. 
Tada et al [6] clearly demonstrated that, after relapse, 
the response rate to therapy inversely correlates with 
the expression of genes related to multidrug resistance 
(MDR1, MRP1, MRP3). Thus, a novel approach has been 
developed for targeting resistance related molecules in 
tumor cells [39, 40].  
In this study, the results of the Cancer Drug 
Resistance and metabolism PCR Array revealed important 
differences between the effects of AN-152 (AEZS-108) 
and DOX on MDR related genes. Chronic treatment with 
DOX resulted in overexpression of most genes involved 
in drug efflux and drug metabolism in RT-4 and HT-1197 
cancers, while AN-152 (AEZS-108) caused reductions 
or smaller increases in these genes. The gene alterations 
seem to persist after therapy cessation. The in vitro 
functional MDR assay also clearly showed differences 
among the bladder cancer cell lines in their reaction to 
a single treatment with DOX or AN-152 (AEZS-108). 
Calcein retention was significantly higher in all cell lines 
after treatment with AN-152, compared to that caused 
by DOX. These differences between the two compounds 
may be explained by an increased uptake by the cells of 
DOX incorporated in the molecule of AN-152 compared 
to unconjugated DOX, and also by a likely decreased 
transporter activity in the presence of AN-152 compared 
to DOX. 
Many enzymes contribute to this intracellular 
metabolism and inactivation of cytotoxic agents; these 
enzymes can be induced or activated by the specific 
drugs. Our investigation revealed important differences 
between the effects of DOX and AN-152 on expression 
of genes related to drug metabolism. A similar pattern was 
observed in DNA repair genes which have important roles 
in responses to therapy. Thus, treatment with platinum 
salts is more effective on tumors which express low levels 
of DNA repair related genes. In the present study, DOX 
caused greater changes than AN-152 in DNA repair related 
genes making tumors less sensitive to therapy. DOX 
resistance can be also associated with changes in proteins 
involved in cell cycle regulation [41]. In our study, cell 
cycle associated genes in three tumor lines were variously 
affected by the treatments. 
Regarding growth factor receptor genes, treatment 
with DOX increased some of these genes, such as ErbB2, 
ErbB4 and FGF2 in the tumors, which are up-regulated in 
bladder cancers and responsible for disease progression 
[42-44]. Moreover, ErbB4 may play a role in DOX-
induced myocardial DNA damage [45]. Our results 
showing that DOX causes a greater increase in ErbB4 than 
AN-152 may explain the lack of cardiotoxicity so far seen 
in preclinical and clinical studies with AEZS-108 [24, 25, 
27]. 
Most hormone receptor related genes analyzed 
were increased by DOX and to a lesser degree by AN-
152. Estrogen receptors have a well-established role in 
bladder cancer progression [46, 47]. Similarly, androgen 
receptors are implicated in bladder carcinogenesis [48, 
49]. The other hormonal receptors investigated, PPARs 
(peroxisome proliferator-activated receptors), RARs 
(retinoic acid receptors) and RXRs (retinoid X receptors) 
can regulate several processes important in tumor 
development, including cell proliferation, differentiation 
and apoptosis. 
Transcription factors are involved in many 
processes, such as growth, differentiation, tumorigenesis 
and apoptosis. Treatment with DOX increased the 
expression of many genes related to transcription factors, 
especially in HT-1197 tumors. Since Karashima et al 
[50] verified that NFkBs (nuclear factor kappB) have a 
role in angiogenesis and metastasis of bladder cancers, 
we selected NFkBs and showed that NFkB was strongly 
increased by DOX but not by AN-152. 
Pro- and anti-apoptotic genes in the tumors were 
affected differently by chronic administration of the 
two drugs. DOX changed pro-apoptotic genes, more 
favorably particularly in RT-4 cancers. DOX also strongly 
increased the expression of many anti-apoptotic genes; 
AN-152 caused fewer changes in these. Our short in vitro 
study revealed that both DOX and AN-152 significantly 
increased apoptosis in all three tumors. They acted 
similarly on J-82 cells and the apoptogenic action of AN-
152 was much stronger than that of DOX on RT-4 and 
HT-1376 cancer cells. 
The PCR arrays used in this study highlight essential 
differences between the action of AN-152 and DOX on 
various bladder cancers. The PCR arrays investigate 
a wide spectrum of tumor characteristics; our study 
analyzed over 150 genes. The pattern of changes, rather 
than individual changes in expression of single genes 
seemed to be more important. The functional pathways of 
groups of genes are interconnected. Thus, we separately 
investigated genes that affect cell cycle and transcription 
factors or those involved in DNA repair, but the combined 
effect determines whether a drug such as DOX will induce 
cell cycle arrest, repair, proliferation or apoptosis [51]. 
Summarizing the results of our study, we showed 
the expression of LH-RH receptors in tumors of 18 
patients.  We then demonstrated that cytotoxic LH-RH 
analog, AN-152, powerfully inhibits the growth of HT-
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1376, J82, RT-4 and HT-1197 human urinary bladder 
cancer lines xenografted into nude mice. All four lines 
express high affinity binding sites for LH-RH. The effect 
of AN-152 is stronger than that of DOX. Treatment with 
DOX activated strong multidrug resistance mechanisms 
in RT-4 and HT-1197 cancers, while AN-152 had little 
or no such effect. Based on our results, we suggest using 
these LHRH receptors for targeted cytotoxic treatment of 
bladder cancers with AN-152 (AEZS-108).  
MATERIALS AND METHODS
Ethics Statement
Investigation has been conducted in accordance with 
the ethical standards and according to the Declaration of 
Helsinki and according to national and international 
guidelines and has been approved by the authors’ 
institutional review board.
Detection of LH-RH receptors in human bladder 
cancer specimens
Surgically removed specimens of 18 human primary 
urothelial bladder carcinomas were fixed in 4% neutral 
buffered formalin and embedded in paraffin. Sections 
were mounted on silanated glass slides (Sigma), and 
dried. For antigen retrieval, slides were immersed in 
10mM citrate buffer, pH 6.0, heated for 15 min and then 
cooled to room temperature (RT).  For immunostaining, 
the sections were blocked in 3% H2O2 in methanol for 10 
min followed by BSA in Tris-buffered saline containing 
0.1% Tween-20, pH 7.4 (TBS-T) for 1 h, and then 
incubated with primary LH-RH receptor antibody (A. 
Menarini Diagnostics, Germany) for 1 h at RT. Sections 
were incubated with peroxidase-conjugated mouse specific 
goat IgG (1:300, Dako, Real Envision, HRP Mouse) for 
30 min at RT with color development over 30 sec to 10 
min in diaminobenzidine. LH-RH receptor expression 
in malignant cells was graded as absent (-; LH-RHR 
expression in 0% of cells), weak expression (+; LH-RHR 
expression in 1-25% of cells), distinct expression (++; LH-
RHR expression in 26-75% of cells) and strong expression 
(+++; LH-RHR expression in 75-100% of cells). Human 
pituitary (anterior lobe) served as positive control. For 
negative control, staining was performed without primary 
LH-RHR antibody. Two observers (GK and DB) graded 
tissues independently. The study was approved by the 
hospital ethics and research committees.
Materials
Cytotoxic LH-RH analog, AN-152 (AEZS-108), 
and LH-RH antagonist, Cetrorelix, first synthesized in 
our laboratory [16] were provided by AEterna/Zentaris 
(Frankfurt am Main, Germany). [D-Trp6]LH-RH was 
obtained from Bachem (Torrance, CA, USA). DOX and 
other chemicals were purchased from Sigma (St. Louis, 
MO, USA). For treatment, the cytotoxic compounds were 
dissolved in 0.01% acetic acid, diluted with 5% mannitol 
and injected at 0.2 ml/20 g body weight.
Animals and tumors
Female athymic nude mice (Ncr nu/nu) were from 
Charles River Laboratories International, Inc. (Durham, 
NC, USA) and Harlan Laboratories (Tampa, FL, USA). 
HT-1376, J82, RT-4 and HT-1197 tumor cells were from 
American Type Culture Collection (ATCC; Manassas, 
VA, USA). In vivo studies were performed using a 
subcutaneous xenograft model, which was induced as 
reported previously [52]. Briefly, six million cells were 
injected sc. into donor animals and 2 mm3 pieces of 
grown tumors were transplanted sc. into both flanks areas 
of experimental animals.  The mice with grown tumors 
were randomly divided into groups of 7-8 mice each and 
treatment started. At experiments completion the mice 
were sacrificed, tumors and organs weighed and frozen. 
Experimental protocol
Experiment 1.
HT-1376 tumors were transplanted sc. into 45 mice; 
treatment was started 85 days later (day 1). The groups 
were: 1) Control, 5% mannitol iv on days 1, 12, 20, 27, 
34; 2) Cetrorelix, (depot preparation), 3 mg/mouse sc. on 
days 1, 22 and 43; 3) D-Trp6LH-RH, 25 µg/day/mouse sc 
daily; 4) AN-152 6.9 µmol/kg iv. on days 1, 12, 20, 27, 34; 
5) DOX, 6.9 µmol/kg iv. on days 1, 12, 20, 27, 34.  The 
experiment ended on day 61. The same doses of AN-152 
and DOX were used in experiment 2, 3, and 4..
Experiment 2 .
J82 cancers were xenografted sc. into 36 mice. 
The treatment started 47 days after transplantation as 
follows: Group 1: Control; Group 2: AN-152 and Group 
3: DOX, both given iv on days 1, 8, 15, 22, 29, 36 and 43. 
Experiment terminated at 136 days. 
Experiment 3. 
RT-4 tumors were transplanted sc. into 32 mice; 
treatment started 49 days later (day 1). The groups: 1. 
Control; 2. AN-152; 3. DOX .  Cytotoxic agents were 
administered iv. once weekly for 7 weeks. The controls 
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received vehicle iv.   Experiment terminated at 100 days. 
Experiment 4. 
HT-1197 cancers were transplanted sc. into 40 mice. 
The treatment started 98 days later (day 1). The groups 
were: 1. Control, 2. AN-152; 3. DOX. The compounds 
were injected iv. on days 1, 5, 8, 12, 15, and AN-152 once 
more on day 30.  Mice were sacrificed at 66 days .
Receptor binding assays
Binding characteristics of receptors for LH-RH 
were determined by analyzing the binding of 125I-labeled 
[D-Trp6]LH-RH to tumor membrane homogenates from 
control mice as described [20]. 
Molecular analysis
Total RNA was isolated from homogenized tumor 
samples from each group using the NucleoSpin kit 
(Macherey-Nagel, Bethlehem, PA, USA). Three samples 
per group were analyzed. Quality control of RNA samples 
was done as previously reported [53].The Human Cancer 
Drug Resistance & Metabolism and the Human Apoptosis 
RT Profiler PCR Arrays (Qiagen, Inc. Valencia, CA, USA) 
were used to analyze mRNA levels of genes related to 
drug metabolism and apoptosis in tumors. Synthesis of 
cDNA, and real-time RT-PCR arrays were performed as 
described [54, 55]. Fold-changes in gene expression were 
calculated using the ΔΔCt method. Five housekeeping 
genes were used for normalization of the results.
For Western blots, bladder tumor tissue was 
processed as described [56]. Briefly, isolated proteins were 
sonicated and the lysates adjusted to equal concentrations. 
Primary antibodies for LH-RH receptors were purchased 
from Abcam (ab 58561 Cambridge, MA, USA), and for 
Bcl2 and BclX from Cell Signaling #2876 (Danvers, MA, 
USA) and Santa Cruz sc-8392 (Santa Cruz, CA, USA), 
respectively. The immunoreactive bands were visualized 
with the Odyssey Infrared Imaging System, using 3.0 
software (LI-COR Biosciences, Lincoln, NE, USA). 
In vitro analysis of multi-drug resistance (MDR) 
HT-1376, J82, and RT4 cells (105 per well) were 
seeded onto 96-well plates, cultured for 48 hours, and 
then treated for 4 hours with AN-152, [D-Trp6]LH-RH, 
DOX or the combination of [D-Trp6]LH-RH and DOX at 
a concentration of 1μM. As positive controls, cyclosporine 
A and verapamil were used (1:1000). Drug resistance 
was evaluated by using the Multi-Drug Resistance Assay 
Kit (Calcein AM) (Cayman Chemicals, Ann Arbor, MI). 
Fluorescence was measured in a Victor 3 Multilabel 
Counter (Perkin-Elmer, Waltham, MD) with excitation and 
emission wavelengths of 485 nm and 535 nm, respectively.
In vitro analysis of apoptosis
HT-1376, J82, and RT4 cells (105 per well) were 
seeded onto 96-well plates, cultured for 48 hours, and 
then treated for 1 hour with AN-152, [D-Trp6]LH-RH, 
DOX or the combination of [D-Trp6]LH-RH and DOX 
at a concentration of 1μM. Apoptosis was detected using 
the Multi-Parameter Apoptosis Assay Kit (Cayman 
Chemicals). Fluorescence was measured in a Victor 
3 Multilabel Counter with excitation and emission 
wavelengths of 560 nm and 595 nm, respectively to 
detect the fluorescence of TMRE (tetramethylrhodamine, 
ethyl ester) staining, and with excitation and emission 
wavelengths of 485 nm and 535 nm, respectively to detect 
early stage apoptotic cells stained by Annexin V FITC 
(fluorescein isothiocyanate).
Statistical analysis
Sigmaplot 11.0 program (Systat Software, Inc. 
SigmaPlot for Windows; San Jose, CA, USA) was used 
for statistical evaluation. After analysis of variance, the 
groups were compared with Dunnett’s method or with 
the Mann-Whitney Rank Sum Test and significance was 
accepted at P < 0.05.
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